SCHEMBL18878471

SCHEMBL18878471

NCCSCCNC(=O)c1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 6/20 0.67
▸ LMNA P02545 3/20 0.67
▸ RAB9A P51151 6/20 0.61
▸ NPC1 O15118 5/20 0.61
▸ RECQL P46063 1/20 0.61
▸ ALDH1A1 P00352 3/20 0.58
▸ HPGD P15428 3/20 0.58
▸ CYP1A2 P05177 1/20 0.54
▸ CYP3A4 P08684 1/20 0.54
▸ CYP2C9 P11712 1/20 0.54
▸ CYP2C19 P33261 1/20 0.54
▸ L3MBTL1 Q9Y468 1/20 0.54
▸ GAA P10253 2/20 0.52
▸ POLB P06746 1/20 0.51
▸ EPHX2 P34913 1/20 0.50
▸ PRSS1 P07477 1/20 0.50
▸ CTSG P08311 1/20 0.50
▸ CTRB1 P17538 1/20 0.50
▸ CMA1 P23946 1/20 0.50
▸ NFKB1 P19838 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28272030 0.83 SMN1; SMN2 (0.67) SMN1; SMN2LMNARAB9ANPC1RECQL
SCHEMBL14029065 0.83 SMN1; SMN2 (0.67) SMN1; SMN2LMNARAB9ANPC1RECQL
SCHEMBL731620 0.82 CYP1A2 (0.67) SMN1; SMN2LMNARAB9ANPC1RECQL
SCHEMBL9324910 0.81 SMN1; SMN2 (0.69) SMN1; SMN2LMNARAB9ANPC1RECQL
SCHEMBL10596825 0.81 SMN1; SMN2 (0.63) SMN1; SMN2LMNARAB9ANPC1RECQL
Hydrochloric Acid SCHEMBL1579939 0.80 MEN1 (0.68) SMN1; SMN2LMNARAB9ANPC1RECQL
SCHEMBL10484573 0.80 SMN1; SMN2 (0.71) SMN1; SMN2LMNARAB9ANPC1RECQL
SCHEMBL15023510 0.80 LMNA (1.00) SMN1; SMN2LMNARAB9ANPC1RECQL
SCHEMBL12708236 0.80 NPC1 (0.52) SMN1; SMN2LMNARAB9ANPC1ALDH1A1
SCHEMBL1467538 0.79 NPC1 (0.66) SMN1; SMN2LMNARAB9ANPC1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170144972-A1 METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) CATABASIS PHARMACEUTICALS, INC. 2017-05-25 — — US disclosed
US-20170144972-A1 METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) CATABASIS PHARMACEUTICALS, INC. 2017-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170144972-A1 METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PCSK9, PCSK6, PCSK7 SMN1; SMN2 4499/4885LMNA 529/4885RAB9A 1266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback